Streetbeat News

Stock Prices

VTEX

Analysts have updated their ratings and price targets for Vtex (NYSE:VTEX), showing a positive shift in sentiment. The average 12-month price target has risen by 34.21% to $10.2, with a high of $12.00 and a low of $8.00. Analysts from UBS, JP Morgan, Piper Sandler, B of A Securities, and Morgan Stanley have all raised their price targets, reflecting optimism about Vtex's performance. The company, known for its digital commerce platform, has shown notable revenue growth and profitability, with a revenue growth rate of 33.5% and a net margin of 5.31%, outperforming industry averages.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 4:05 pm

CGTX

Cognition Therapeutics (NASDAQ:CGTX) is scheduled to release its quarterly earnings report on 2024-03-26, with an estimated EPS of $-0.34. Investors are hopeful for a beat on this estimate and positive guidance for the next quarter. Historically, CGTX has shown a mixed reaction to earnings reports, with share price movements varying post-announcement. Currently, shares are trading at $1.81, down 10.78% over the last 52 weeks.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 4:05 pm

DWAC

Digital World Acquisition Corp (NASDAQ:DWAC) shares rose after shareholders approved its merger with Trump Media & Technology Group Corp. The merger's approval was announced after market close on Friday, with a significant majority in favor. Post-merger, Trump Media & Technology Group Corp will trade on Nasdaq under the symbols 'DJT' and 'DJTWW'. DWAC's stock was up 8.69% at $40.13 at the time of publication.

Portfolio Pulse from Adam Eckert

March 25, 2024 | 4:05 pm

PAVM

PAVmed Inc. (NASDAQ:PAVM) is scheduled to release its quarterly earnings report on March 26, 2024, with analysts expecting an EPS of $-1.89. The company's past earnings performance shows a mixed record of beating and missing EPS estimates, leading to varied stock price reactions. Shares of PAVmed have declined by 55.27% over the last 52 weeks, indicating a bearish sentiment among long-term shareholders. Investors will be keenly watching for the company's performance against the EPS estimate and any forward-looking guidance provided.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 4:05 pm

ALV

Over the last three months, Autoliv (NYSE:ALV) has been evaluated by 5 analysts, showing a positive shift in sentiment with an increase in the average 12-month price target to $113.8 from $105.40. Analysts from Mizuho and Barclays have raised their price targets, reflecting optimism in Autoliv's financial performance, which includes a solid revenue growth rate of 17.82% and impressive net margin and ROE figures. Autoliv is recognized as a global leader in passive safety components for the auto industry.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 4:05 pm

PBLA

Panbela Therapeutics (NASDAQ:PBLA) is scheduled to release its quarterly earnings report on March 26, 2024, with an estimated EPS of $-24.34. Historical data shows mixed reactions to past earnings reports, with the last quarter missing EPS estimates and resulting in a 2.66% share price increase the following day. Over the past year, PBLA shares have declined by 99.79%, indicating significant investor concern ahead of this earnings announcement.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 4:05 pm

PUBM

Analyst reviews for PubMatic (NASDAQ:PUBM) over the last three months show diverse outlooks, with recent ratings becoming more bullish. The average 12-month price target has increased to $26.00, reflecting a 34.51% rise from the previous target of $19.33. PubMatic's financial performance is strong, with significant revenue growth, high net margin, and excellent ROE and ROA, outperforming industry averages. The company's debt management is also sound, indicating a robust financial structure.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 4:05 pm

LUXH

LuxUrban Hotels (NASDAQ:LUXH) is scheduled to release its quarterly earnings report on March 26, 2024, with analysts expecting an EPS of $0.09. The company's past earnings performance shows mixed results, with a miss last quarter but a subsequent 7.5% share price increase. Over the last year, LUXH shares have decreased by 2.58%, indicating potential concern among long-term shareholders. Investors will be keenly watching for not only the earnings results but also the company's future guidance.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 4:05 pm

DJT

DWAC

The SPAC merger between Digital World Acquisition Corporation (DWAC) and Trump Media & Technology Group (TMTG) was approved, with TMTG set to debut on Nasdaq under the ticker DJT. Shareholders who redeemed shares at net asset value missed out on higher market prices. DWAC's stock is expected to see significant volatility.

Portfolio Pulse from Chris Katje

March 25, 2024 | 4:05 pm

MRAI

Marpai (NASDAQ:MRAI) is scheduled to release its quarterly earnings report on 2024-03-26, with analysts expecting an EPS of $0.00. Investors are hopeful for positive guidance for the next quarter. Marpai's stock performance has been negative over the last year, with a 37.88% decrease. The company's past earnings have shown a trend of beating EPS estimates but with mixed impacts on stock price.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 4:05 pm